This is a good sign and perhaps the first of many such news articles linking PRR with DNDN's success!!
CHEERS
BIRDSEYE
FDA Approval For Dendreon Provenge Immunotherapy Vaccine
Published: 30-Apr-2010.
Nasdaq-listed company Dendreon has received approval from FDA to commence sales of its Provenge immunotherapy vaccine for the treatment of prostate cancer.
Dendreon plans to have three plants to make Provenge by mid of 2011. According to an estimate by Bloomberg the drug is expected to generate $1.2bn by 2014.
Dendreon is using cancer immunotherapies that use the patient's own immune system to treat cancer and the approval of Provenge represents a scientific and clinical advancement for the treatment of prostate cancer.
Prima BioMed, an Australian biotechnology firm focused on cancer immunotherapy, is using the technology to develop its CVac immunotherapy cancer vaccine for the treatment of ovarian cancer.
Prima BioMed said that the approval of Provenge represents a transformational event in the development of cancer treatments and is expected to create a new treatment paradigm for patients with cancer.
source: http://regulatoryaffairs.pharmaceutical-business-review.com/news/fda_approval_for_dendreon_provenge_immunotherapy_vaccine_100430/
- Forums
- ASX - By Stock
- IMM
- prr mentioned with dndn in usa news release
prr mentioned with dndn in usa news release
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
31.0¢ |
Change
-0.005(1.59%) |
Mkt cap ! $458.1M |
Open | High | Low | Value | Volume |
31.5¢ | 31.5¢ | 31.0¢ | $32.61K | 104.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
40 | 310639 | 31.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
31.5¢ | 158616 | 59 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
40 | 310639 | 0.310 |
24 | 269807 | 0.305 |
26 | 458755 | 0.300 |
11 | 119670 | 0.295 |
11 | 295739 | 0.290 |
Price($) | Vol. | No. |
---|---|---|
0.315 | 158616 | 59 |
0.320 | 188677 | 17 |
0.325 | 246937 | 7 |
0.330 | 66808 | 6 |
0.335 | 335213 | 9 |
Last trade - 12.50pm 07/10/2024 (20 minute delay) ? |
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
IMM (ASX) Chart |